Abstract 52: Clinical efficacy of dapagliflozin in patients with newly diagnosed type 2 diabetes

Background: The world is facing epidemic of diabesity (diabetes and obesity). Treating both the conditions can be difficult. There are limited available medicines that can treat both diabetes and obesity. Dapagliflozin (SGLT2 Inhibitor) is one such drug which can decrease body weight and obesity in diabetes patients. In present study we have tried to study the clinical efficacy and safety of dapagliflozin 10 mg used alone in patients with new onset diabetes and obesity. Aims and Objectives: To detect the clinical efficacy of dapagliflozin on newly diagnosed type 2 diabetes patients. To evaluate the adverse effects associated with dapagliflozin. Results: We studied the efficacy of dapagliflozin 10 mg in 50 newly diagnosed type 2 diabetes patients with overweight and obesity for 1 year duration. 30 patients had BMI >30, 10 had BMI 28-30, and 10 had BMI 25-28. All patients had hba1c>9% on diagnosis. Dapagliflozin 10 mg od resulted in reduction of hba1c of around 2% over 1 year duration. Weight reduction was about 5-10 kg in all patients. More weight reduction was found in patients with high BMI >30. BP decreased by about 20 mm of systolic and 10 mm hg of diastolic in patients with hypertension. Major adverse effects were genitourinary candidiasis in 10 patients and uncomplicated uti in 5 patients. Conclusion: Dapagliflozin 10 mg od used in newly diagnosed obese and overweight type 2 diabetes patients was very useful in reducing weight of about 5-10 kg and hba1c of about 2%. It was also found to be useful in reducing blood pressure and reducing number of other antihypertensive medicines.